Revvity (LSE:0KHE) - Stock Price, News & Analysis

0KHE Stock Overview

Revvity, Inc. ofrece soluciones, tecnologías y servicios de ciencias de la salud en América, Europa y Asia, así como a escala internacional.

About the company

0KHE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Cotiza un 43.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 24.05%

Risk Analysis

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (6.5%) son inferiores a los del año pasado (15.5%)

Revvity, Inc. Competitors

Ergomed

AIM:ERGO

UK£701.1m

hVIVO

AIM:HVO

UK£200.0m

Hikma Pharmaceuticals

LSE:HIK

UK£4.1b

Divi's Laboratories

NSEI:DIVISLAB

₹1.0t

Price History & Performance

Summary of all time highs, changes and price drops for Revvity
Historical stock prices
Current Share Price	US$106.25
52 Week High	US$138.90
52 Week Low	US$79.50
Beta	1.09
1 Month Change	-2.88%
3 Month Change	-4.95%
1 Year Change	-21.15%
3 Year Change	-14.50%
5 Year Change	9.25%
Change since IPO	28.40%

Recent updates

Shareholder Returns

	0KHE	GB Life Sciences	GB Market
7D	4.9%	-5.5%	-0.01%
1Y	-21.2%	-36.7%	0.8%

Rentabilidad frente al sector: 0KHE superó al sector UK Life Sciences , que obtuvo un rendimiento del -16.7% el año pasado.

Rentabilidad vs. Mercado: 0KHE obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.

Price Volatility

Is 0KHE's price volatile compared to industry and market?
0KHE volatility
0KHE Average Weekly Movement	3.8%
Life Sciences Industry Average Movement	8.2%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0KHE no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0KHE (5%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1937	11,500	Prahlad Singh	https://www.revvity.com

Revvity, Inc. ofrece soluciones, tecnologías y servicios de ciencias de la salud en América, Europa y Asia, así como a escala internacional. El segmento de ciencias de la vida proporciona instrumentos, reactivos, informática, software, suscripciones, detección, tecnologías de imagen, garantías, formación y servicios. Su segmento Diagnostics suministra instrumentos, reactivos, plataformas de ensayo y productos de software para la detección precoz de trastornos genéticos, como el embarazo y la primera infancia, así como pruebas de enfermedades infecciosas en el mercado del diagnóstico.

Revvity, Inc. Fundamentals Summary

How do Revvity's earnings and revenue compare to its market cap?
0KHE fundamental statistics
Market cap	US$13.14b
Earnings (TTM)	US$179.50m
Revenue (TTM)	US$2.75b

73.2x

P/E Ratio

4.8x

P/S Ratio

Is 0KHE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0KHE income statement (TTM)
Revenue	US$2.75b
Cost of Revenue	US$1.21b
Gross Profit	US$1.54b
Other Expenses	US$1.36b
Earnings	US$179.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 29, 2024

Earnings per share (EPS)	1.45
Gross Margin	55.98%
Net Profit Margin	6.53%
Debt/Equity Ratio	49.5%

How did 0KHE perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

19%

Payout Ratio

Does 0KHE pay a reliable dividends?

See 0KHE dividend history and benchmarks

When do you need to buy 0KHE by to receive an upcoming dividend?
Revvity dividend dates
Ex Dividend Date	Apr 18 2024
Dividend Pay Date	May 10 2024
Days until Ex dividend	8 days
Days until Dividend pay date	30 days

Does 0KHE pay a reliable dividends?

See 0KHE dividend history and benchmarks

0KHE Stock Overview

Rewards

Risk Analysis

Revvity, Inc. Competitors

AIM:ERGO

UK£701.1m

AIM:HVO

UK£200.0m

LSE:HIK

UK£4.1b

NSEI:DIVISLAB

₹1.0t

Price History & Performance

Recent News & Updates

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Recent updates

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

New minor risk - Earnings quality

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

New major risk - Revenue and earnings growth

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.55 in 3Q 2022)

New minor risk - Earnings quality

Investor sentiment deteriorates as stock falls 21%

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

New minor risk - Earnings quality

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.47 (vs US$1.33 in 2Q 2022)

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings released: EPS: US$0.20 (vs US$1.40 in 1Q 2022)

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

Upcoming dividend of US$0.07 per share

Now 20% undervalued

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021)

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021)

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors